2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 844

Social Support, Stress and Health Outcomes in Systemic Lupus Erythematosus: Georgians Organized Against Lupus (GOAL) Cohort
Abstract Number: 1665

Soluble Programmed Cell Death Protein 1 As a Biomarker for Systemic Lupus Erythematosus
Abstract Number: 454

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Correlates with Disease Activity in Early Rheumatoid Arthritis and Reflects Joint Damage over Time
Abstract Number: 677

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Predicts the Development of Organ Damage over 5 Years in Systemic Lupus Erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Abstract Number: 2809

Spatial Navigation Impairment Associated with Anti-NMDA Receptor Antibodies in Systemic Lupus Erythematosus
Abstract Number: 30

Specificity of Salivary Gland-Derived Monoclonal Antibodies from Sjogren’s Syndrome Patients Using Human Proteome Arrays
Abstract Number: 1164

Spectrum of Skin Eruption and Histological Findings in Adult-Onset Still’s Disease and Significance of Atypical Persistent Skin Eruptions
Abstract Number: 1790

Sphingosine -1 Phosphate Receptor-1-Mediated Endothelial Cell Barrier Function Protects Against Immune Complex-Induced Vascular Injury: A Potential Novel Therapeutic Target for SLE
Abstract Number: 2560

Spleen Tyrosine Kinase Inhibition Reveals Immune Cell Subsets of Diseased NZB/W F1 Mice That Are Reflected in Systemic Lupus Erythematosus Patient Peripheral Blood Mononuclear Cells
Abstract Number: 484

Sputum Neutrophils Demonstrate Increased Neutrophil Extracellular Trap Formation in RA-Free Subjects at-Risk of Future RA
Abstract Number: 690

SSA Antibodies Are Associated with Valvular Abnormalities in SLE Patients without Clinical Cardiovascular Disease
Abstract Number: 1262

Stability of Two Short Medication Adherence Questionnaires over Time for Follow-up in Patients with Rheumatoid Arthritis
Abstract Number: 1088

Staff Protocol in Rheumatology Clinics Reduces Population-Level Rate of High Blood Pressure
Abstract Number: 1451

Starting of Biological Dmards May be Postponed in RA Patients with Multimorbidity: Single Centre Real Life Results
Abstract Number: 2928

STAT3 As an Important Integrator of Profibrotic Pathways in Systemic Sclerosis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].